| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.38 | 3e-31 |
| mRNA | ML239 | CTRPv2 | pan-cancer | AAC | 0.22 | 4e-10 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | 0.22 | 3e-09 |
| mRNA | NVP-BSK805 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-09 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.2 | 5e-09 |
| mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | 0.21 | 8e-09 |
| mRNA | dexamethasone | CTRPv2 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | prima-1 | CTRPv2 | pan-cancer | AAC | -0.14 | 1e-05 |
| mRNA | Nilotinib | CCLE | pan-cancer | AAC | 0.2 | 4e-05 |
| mRNA | Zibotentan | GDSC1000 | pan-cancer | AAC | 0.13 | 9e-05 |